PMV Pharmaceuticals reported a net loss of $21.2 million for Q2 2025, a significant increase from $1.2 million in Q2 2024, primarily due to a $16.2 million income tax benefit in the prior year that did not recur. Research and development expenses rose to $18.4 million, while general and administrative expenses decreased to $4.5 million. The company ended the quarter with $148.3 million in cash, cash equivalents, and marketable securities.

PMV Pharmaceuticals reported a net loss of $17.4 million for Q1 2025, an increase from $15.3 million in Q1 2024. The company maintained a strong cash position of $165.8 million, providing a cash runway to the end of 2026. Research and development expenses increased due to the advancement of product candidates, while general and administrative expenses decreased.

PMV Pharma reported cash, cash equivalents, and marketable securities of $183.3 million as of December 31, 2024. Net loss for the year ended December 31, 2024, was $58.7 million. Enrollment is on track in Phase 2 pivotal portion of PYNNACLE clinical trial.

PMV Pharmaceuticals reported a net loss of $19.2 million for the third quarter of 2024, compared to a net loss of $16.6 million for the third quarter of 2023. The company ended the quarter with $197.9 million in cash, cash equivalents, and marketable securities.

PMV Pharmaceuticals reported financial results for the second quarter ended June 30, 2024. The company's net loss for the quarter was $1.2 million, and they ended the quarter with $212.9 million in cash, cash equivalents, and marketable securities.

PMV Pharma reported first quarter financial results, highlighting the dosing of the first patient in the Phase 2 portion of the PYNNACLE trial and a cash, cash equivalents, and marketable securities balance of $213.1 million as of March 31, 2024.

PMV Pharmaceuticals reported its full year 2023 financial results, with a focus on the advancement of rezatapopt and the extension of the company's cash runway to the end of 2026 through cost savings initiatives. The registrational Phase 2 clinical trial for rezatapopt remains on track to initiate in Q1 2024.

PMV Pharma reported its Q3 2023 financial results, featuring updated Phase 1 data from the PYNNACLE clinical trial, demonstrating efficacy and safety of PC14586. The company ended the quarter with $238.1 million in cash, cash equivalents, and marketable securities.

PMV Pharmaceuticals reported its Q2 2023 financial results, highlighting continued progress in the PYNNACLE study of PC14586 and a successful End-of-Phase 1 FDA meeting. The company ended the quarter with $218.8 million in cash, cash equivalents, and marketable securities.

PMV Pharmaceuticals reported a net loss of $19.1 million for the quarter ended March 31, 2023, compared to a net loss of $18.4 million for the quarter ended March 31, 2022. The company ended the quarter with $229.4 million in cash, cash equivalents, and marketable securities.

PMV Pharmaceuticals reported cash, cash equivalents, and marketable securities of $243.5 million as of December 31, 2022. Net loss for the year ended December 31, 2022, was $73.3 million. The company is focusing on clinical development of PC14586 and the pipeline program R282W.

PMV Pharmaceuticals reported their Q3 2022 financial results, highlighting the continued advancement of the PYNNACLE study evaluating PC14586 and plans for the initiation of a clinical trial of PC14586 in combination with KEYTRUDA.

PMV Pharmaceuticals reported its Q2 2022 financial results, highlighting positive initial data from the PYNNACLE study of PC14586 presented at ASCO and a clinical collaboration with Merck to evaluate PC14586 in combination with KEYTRUDA®.

PMV Pharmaceuticals reported a net loss of $18.4 million for the quarter ended March 31, 2022. As of March 31, 2022, the company had $294.8 million in cash, cash equivalents, and marketable securities.

PMV Pharma reported its Q4 and full year 2021 financial results, with a focus on the continued development of PC14586 and the expansion of its pipeline. The company ended the year with a strong cash position of $314.1 million.

PMV Pharma reported its Q3 2021 financial results, highlighting the progress of its lead candidate, PC14586, and a strong cash position of $326.3 million to support operations through 2023.

PMV Pharmaceuticals reported its Q2 2021 financial results, highlighting the continued enrollment in the Phase 1/2 trial of PC14586 and ending the quarter with $339.0 million in cash, cash equivalents, and marketable securities.

PMV Pharma reported a net loss of $11.6 million for the quarter ended March 31, 2021. The company ended the quarter with $348.4 million in cash, cash equivalents, and marketable securities. Enrollment in the Phase 1/2 trial of PC14586 is progressing as planned.

PMV Pharmaceuticals reported its Q4 and full year 2020 financial results, highlighting the initiation of Phase 1/2 study of PC14586 and a strengthened financial position with $361.4 million in cash, cash equivalents, and marketable securities.

PMV Pharma reported a net loss of $8.8 million for the quarter ended September 30, 2020. The company ended the quarter with $373.1 million in cash, cash equivalents, and marketable securities. The FDA cleared the IND application for lead product candidate PC14586.